Table 1.
Statin-naïve patients (n = 76) | Statin users (n = 22) | p value | |
---|---|---|---|
Center | 0.102 | ||
South Korean | 30 (39.5) | 13 (59.1) | |
Southern Californian | 46 (60.5) | 9 (40.9) | |
Age, years | 68.9±14.31 | 77±7.62 | 0.031 |
Female gender | 48 (63.2) | 13 (59.1) | 0.729 |
Hypertension | 43 (56.6) | 18 (81.8) | 0.032 |
Diabetes | 11 (14.5) | 5 (22.7) | 0.345 |
Current smoking | 7 (9.2) | 4 (18.2) | 0.260 |
Dyslipidemia | 7 (9.3) | 14 (66.7) | <0.001 |
Previous stroke | 20 (26.3) | 5 (22.7) | 0.734 |
Previous coronary heart disease | 13 (17.1) | 9 (40.9) | 0.039 |
NIH stroke scale | 17 [15–20] | 19 [14–23] | 0.343 |
Systolic blood pressure, mm Hg | 155 [137–176] | 160 [145–170] | 0.327 |
Time from onset to TFCA, min | 240 [191.5–328.5] | 263 [197–396] | 0.558 |
Intravenous t-PA treatment | 43 (56.6) | 9 (40.9) | 0.223 |
Blood pressure medication | |||
β-Blocker | 19 (33.3) | 11 (57.9) | 0.058 |
Ca2+ channel blocker | 8 (15.4) | 3 (15.8) | 1.000 |
ARB/ACE inhibitor | 20 (28.6) | 9 (42.9) | 0.218 |
Antithrombotic agent | 0.190 | ||
Antiplatelets | 27 (36) | 12 (60) | 0.072 |
Warfarin | 14 (18.7) | 4 (20) | 1.000 |
Aspirin + warfarin | 3 (4) | 0 (0) | 1.000 |
Laboratory findings, mg/dl | |||
Glucose | 123.3±27.78 | 137.8±46.89 | 0.441 |
Triglyceride | 90.3±47.82 | 121.2±47.82 | 0.004 |
HDL cholesterol | 50.2±18.28 | 47.0±26.16 | 0.105 |
LDL cholesterol | 104.3±31.67 | 77.1±18.16 | <0.001 |
Excellent collateral | 0.049 | ||
Absence | 55 (72.4) | 11 (50) | |
Presence | 21 (27.6) | 11 (50) |
Statistically significant p values are highlighted in italics. Values are represented as means ± SD, numbers with percentages in parentheses or medians with interquartile ranges in square brackets. ARB = Angiotensin II receptor blocker; ACE = angiotensin-converting enzyme; TFCA = transfemoral cerebral angiography; t-PA = tissue-type plasminogen activator; HDL = high-density lipoprotein; LDL = low-density lipoprotein.